cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Recruiting
N/A
Interventional Study
Locally Advanced Head and Neck Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 59 (estimated)
- Sponsor
- Centre Jean Perrin · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
The main question it aims to answer is :
\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-mont…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Selection Criteria:
* Patient included in NeckTAR study
* Written informed consent signed for NeckTAR-IN study
* Affiliation to the French social security system
Contacts